



Notification 6380 / 6381

Category

HCPCS - Drugs & Biologicals

Topic

Factor VIIa Antihemophilic NovoSeven

What is changing?

HUM     6380     Factor VIIa  
Antihemophilic  
cNovoSeven

We apply the following reimbursement limitations on charges for Factor VIIa antihemophilic NovoSeven if submitted a diagnosis of Glanzmann's thrombasthenia:

- No more than 47,800 units per date of service for ages younger than 5
- No more than 106,512 units per date of service for ages 5 – 10
- No more than 228,480 units per date of service for ages 10 or older

HUM     6381     Factor VIIa  
Antihemophilic  
cNovoSeven

We apply the following limitations for charges of Factor VIIa antihemophilic NovoSeven if submitted a diagnosis of hereditary factor VIII deficiency with inhibitors or hereditary factor IX deficiency with inhibitors:

- No more than 47,800 units per date of service for ages younger than 5
- No more than 106,512 units per date of service for ages 5 – 10
- No more than 228,480 units per date of service for ages 10 or older

Language

English

Impacted Products

Medicaid – Louisiana

Why is Humana making this change?

The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia. Note: The limitations described above are based on maximum dosages established in micrograms. If any units are denied, the provider may dispute the decision through the appropriate process. The provider may submit information, including medical notes showing the patient's body weight, which substantiates the medical necessity of the additional units.